SCHEMBL4679502

SCHEMBL4679502

O=C(Cc1cc(S(=O)(=O)c2ccc(Cl)cc2)co1)C(=O)c1nn[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 4/20 0.35
NAMPT P43490 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 1/20 0.35
MAPK1 P28482 1/20 0.35
TBXA2R P21731 1/20 0.34
CYP2C19 P33261 1/20 0.32
AKR1B1 P15121 1/20 0.32
KDM1A O60341 2/20 0.31
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
CHEK2 O96017 1/20 0.31
MITF O75030 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
PAX8 Q06710 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CNR1 P21554 1/20 0.31
PYGL P06737 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679159 0.90 CES1 (0.36) NAMPTALDH1A1MAPK1CYP2C19LMNA
SCHEMBL4671572 0.89 NAMPT (0.35) CXCR3NAMPTCYP2C19AKR1B1CA2
SCHEMBL4677188 0.83 NAMPT (0.35) NAMPTALDH1A1CYP3A4MAPK1AKR1B1
SCHEMBL4671388 0.82 CXCR3 (0.36) CXCR3ALDH1A1CYP3A4MAPK1TBXA2R
SCHEMBL4676471 0.81 CXCR3 (0.35) CXCR3NAMPTALDH1A1CYP3A4MAPK1
SCHEMBL4673305 0.80 CXCR3 (0.35) CXCR3NAMPTALDH1A1CYP3A4MAPK1
SCHEMBL4672179 0.79 LOX (0.37) CXCR3ALDH1A1CYP3A4MAPK1
SCHEMBL4679761 0.79 ALDH1A1 (0.36) CXCR3NAMPTALDH1A1CYP3A4MAPK1
SCHEMBL4673905 0.78 CXCR3 (0.35) CXCR3NAMPTALDH1A1CYP3A4MAPK1
SCHEMBL4672144 0.78 CXCR3 (0.35) CXCR3NAMPTALDH1A1CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CXCR3 1130/4885NAMPT 2333/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.